

Aurangabad, August 13, 2016

**Wockhardt Q1FY17 Net Sales at Rs.1,091 crore and PAT at Rs.16 crore**

	Q1FY17	Q4-FY16	Q1-FY16
	Apr - Jun	Jan - Mar	Apr - Jun
	2016	2016	2015
	Rsc	Rsc	Rsc
<b>Sales</b>	<b>1,091</b>	<b>1,011</b>	<b>1,139</b>
<b>EBITDA excl "one offs &amp; R&amp;D"</b>	<b>193</b>	<b>145</b>	<b>176</b>
<b>EBITDA % to Sales</b>	<b>17.7%</b>	<b>14.3%</b>	<b>17.5%</b>
<b>EBITDA</b>	<b>85</b>	<b>72</b>	<b>165</b>
<b>EBITDA Margins %</b>	<b>7.8%</b>	<b>7.1%</b>	<b>14.5%</b>
<b>Profit After Tax</b>	<b>16</b>	<b>(8)</b>	<b>92</b>
<b>PAT Margins %</b>	<b>1.5%</b>	<b>-0.8%</b>	<b>8.1%</b>
<b>EPS</b>	<b>1.4</b>	<b>(0.7)</b>	<b>8.4</b>

Results for the Quarter ended June 30, 2016 are in compliance with the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs. Consequently, the results for the Quarter's ended March 31, 2016 and June 30, 2015 have also been restated to comply with Ind AS and make it comparable.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1<sup>st</sup> Quarter results for Financial Year 2017, today.

The Company's UK business (excluding one-time opportunity) displayed strong performance and grew by 26% in Q1FY17 compared to Q1FY16. The Company made 3 new filings and received 1 new approval in UK market. India Business of the Company grew by 10% during the quarter compared to Q1FY16 on account of continued new products launches and focused strategies on various therapies. 11 new products were launched in India during the quarter.

The company continued its pursuit of creating a strong Intellectual Property (IP) base and filed 97 patents during the Quarter ended 30<sup>th</sup> June, 2016 taking the cumulative filings to 2676. The company was granted 14 patents during the quarter and now totally holds 455 patents.

### **Quarter ended 30<sup>th</sup> June, 2016**

Consolidated revenue for Q1FY17 was Rs.1,091 crore (excluding one off's revenue grew by 8% compared to Q1FY16) and Profit After Tax was at Rs.16 crore.

International Business contributed 62% of the total revenues during the Q1FY17.

EBITDA excluding one-time opportunities and before R&D spend was Rs 193 crore (Margin at 18% to sales) compared to Rs 176 crore (Margin at 17% to sales) in the previous corresponding quarter.

The company continued to focus in Research & Development with quarterly spent at Rs.108 crore (10% to sales) and including capital expenditure is at 14% to sales for the quarter ended Q1FY17.

Capital expenditure of Rs 116 crore was incurred in Q1FY17.

US Business contributed 18% of the Global Revenues and de grew by 16%.

Emerging market business de grew by 16% in Q1FY17.

The Irish Business de grew by 18% in INR terms in Q1FY17.

### **Regulatory Update**

The Company's three units namely L-1 Chikalthana Facility, H-14/2 Waluj Facility and B-15/2 Waluj Facility in Maharashtra have received Establishment Inspection Report (EIR) with observations.

On 5<sup>th</sup> August, 2016 US Food and Drugs Administration (US FDA) posted Import Alert 66-40 on its website on the Company's manufacturing facility for Active Pharmaceutical Ingredients (API) located in Ankleshwar, Gujrat.

The Company has initiated required steps to address the concerns raised by US FDA and is putting all efforts to resolve the matter.

**PRESS RELEASE**

**WOCKHARDT**

**LIFE  
WiNS**

**Wockhardt Limited**

| D-4, MIDC, Chikalthana |  
| Aurangabad |  
| Maharashtra | | 431 006 |  
| India |  
| Tel.: +91-22-2653 4444 |  
| [www.wockhardt.com](http://www.wockhardt.com) |

---

***About Wockhardt :***

Wockhardt is a Global Pharmaceutical company employing over 10,000 people and 27 nationalities with presence in USA, UK, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 62% of its global revenues coming from international businesses. Wockhardt is home to 850 scientists, of whom 100 are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive. Wockhardt's entire Anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.